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Introduction
Vaccine in general can be derived from
live or attenuated virus, killed whole-
cell virus, sub-unit component (LPS,
protein). recombinant vaccine and
DNA or RNA vaccine. Recombinant
and DNA based vaccination constitutes
two of the most recent approaches to
vaccine development. DNA vaccine is
a simple and versatile method of in-
ducing both humoral and cellular re-
sponses to the antigen encoded by the
plasmid. as well as protection against a
variety of infectious agents. VPI is a
capsid protein and it is studied to de-
velop a new DNA vaccine against
CAV.
In recombinant bacterial systems, most
of the bacteria used as vectors are de-
rived from the Gram negative micro-
organisms. The use of Lactococcus as
an alternative vector system has been
considered because it is the genetically-
best characterized lactic acid bacteria
and due to its GRAS (Generally Re-
garded As Safe) status. Currently, there
are several recombinant Lactococcal
strains which has shown the capability
to express heterologous proteins with
vaccine potential (Robinson et al.,
1997). However, the major problem
faced in studies using Lactococcus
system is the lack of commercially
available plasmid vectors in the mar-
ket. Thus. it is important to construct
potential plasmid vectors to be used for
expressions in Lactococcus.
Materials and Methods
Construction a/plasmid DNA.The VPl
gene was amplified and digested with
. £CaRl and KpnI. The 1.4 kb of the
gene was then ligated to the EcoRI -
KpnI double digested pcDNA3.1 vec-
tor. Recombinant plasmid was trans-
formed into E. coli TOP 10 cells using
heat-shock method by Sambrook et al.
(1989). The cells were grown in LB
medium containing ampicillin
(50jlg/ml) and incubated at 37°C.
Vera cells. The plasmid DNA was
transformed into Vero cells (Africa
green monkey kidney cells) by LIPO-
FECTAMINE 200 reagent (Life tech-
nologies). The transfected Vero cells
were cultred in Ll5 medium with 10%
fetal calf serum and I% antibiotics at
37°C. the cells were then sub-cultured
at 2 to 3 days intervals.
Indirect immunofluorescence test. The
transfected Vero cells and untrans-
fected control vero cells were plated on
4 chamber slide (Lab-Tek) respectively
a day before the test. The cells were
fixed in chilled acetone: methanol
(1:1) for 10 min. A 50 jll ofCAV VPI
monoclonal antibody (TropBio) diluted
1: lOOO in PBS was applied to the cells.
After 1 h of incubation at 37°C in a
humidified atmosphere, the slides were
washed 3 times in ,.•,:.
PBS, each time for 15 min. A 50 ul of
a I: 1oo dilution of FITC rabbit anti-
mouse IgG (Kirkegaard and Perry
Laboratories) was then applied to the
cells for 1 h at 37°C and rinsed 3 times
with PBS, each time for 15 min. The
slides were then mounted in buffered
glycerol (pH 7.4) and observed for
flourescence using a flourescence mi-
croscope.
Indirect immunoperoxidase test. The
transfected Vero cells and the untrans-
fected control Vero cells were plated
on 4 chamber slide (Lab-Tek) respec-
tively a day before the test. The cells
were fixed in chilled acetone: methanol
(1:1) for 10 min. Non-specific binding
sites were blocked by incubating the
cells with 5% BSA for 1 h at 37°C.
The blocking solution was then drained
off. A 50 jll of CAV VPl monoclonal
antibody (TropBio) diluted 1: lOoo in
PBS was placed to the cells. After 1 h
of incubation at 37°C in a humidified
atmosphere, the slides were washed 3
times in PBS, each time for 15 min. A
50 jll of a 1:1000 dilution of HRP goat
anti-mouse IgG (Kirkcgaard and Perry
Laboratories) was then applied to the
cells and incubated 1 h at 37°C. The
cells were then rinsed 3 times with
PBS. The slides were then mounted in
buffer glycerol (pH 7.4) and observed
under a light microscope.
Bacterial strains and growth condi-
tions. Lactococcus strain were grown
in Ml7 medium supplemented with
0.5% glucose and incubated at 30°C
where as E. coli strains were grown in
LB medium and incubated at 37°C.
When required, a total concentration of
5 g/ml of erythromycin was used for
Lactococcus while 50 glml of ampicil-
lin were used for E. coli cultures.
Construction o/pMG36enisA. The
genomic DNA of L lactis ATCC strain
11454 was isolated using the method
from Engelke et al. (1992) with minor
modification. The nisA gene was am-
plified by PCR using primers design
based on the published sequence of
nisA gene (Engelke et al., 1992) with
the forward primer carrying an EcoRI
site. The gene itself carries a unique
Sac 1 site downstream of the nisin pro-
moter region. The amplified gene was
then digested with EcoR 1 and Sacl to
obtain the 344 bp DNA fragment con-
taining the promoter region of the nisin
gene. This fragment was then cloned
into the EcoRI - Sac! region of the
expression vector pMG36e (Van de
Guchte et al., 1989). The constructed
plasmid was then transformed into
plasmidless E. coli XLI-Blue (Strata-
gene) using heat-shock method by
Sambrook et al. (1989) and later elec-
tro-transformed into a plasmid less
Lactococcus lactis MG 1363 (Gasson et
al., 1983) using the protocol from
(Holo et al.and Nes, 1989) and selec-
tion was made on media containing
erythromycin. Verification of the con-
struct was done by restriction digestion
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analysis of the plasmid with EcoRI
and Sacl, and by peR amplification of
the cloned promoter region. The newly
constructed plasmid vector was desig-
nated as pMG36eRnisA.
Construction o/pAl03. An erythromy-
cin resistant plasmid (pAJOl) was pre-
viously ligated to the E. coli cloning
vector pUel9 at the EcoRI site re-
sulting a new shuttle vector named
pAJ02 (Raha et al., 2(01). The P32
constitutive promoter together with the
VP3 gene of the CA V from the previ-
ously constructed pMG36e-VP3 re-
combinant plasmid was amplified by
PCR with the forward primer designed
to carry a Kpnl site while the reverse
primer was designed to carry an Xba I
site. The amplified PCR product was
then digested and cloned into the Kpn 1
- Xba I region of the pAJ02. The re-
combinant plasmid designated as pAJ3
was then transformed into E. coli XL 1-
Blue (Stratagene) and electro-
transformed into plasmidless L lactis
MG1363. The transformants were
selected on medium containing ampi-
cillin and erythromycin respectively.
Verification of the transformant was
done by restriction digestion analysis
and PCR amplifycation of the cloned
DNA fragment.
Results and Discussions
The CAV VPl gene was expressed in
the Vero cells. Using indirect immuno-
fluorescent test, the expression of VPl
was observed as green-yellowish fluo-
rescence and the staining was predomi-
nantly in the cytoplasm of the Vero
cells. For the indirect immuno-
peroxidase test, immuno-peroxidase
staining was detected as brownish col-
our also predominantly in the cyto-
plasm. However, both immunostaining
tests indicated low levels of expression
of the VP 1 gene in transfected Vero
cells.
The amplification of the nisA gene,
including the promoter region, resulted
in a PCR product of 415 bp in size. The
forward primer used was designed to
carry an EcoRI site, while the down-
stream of the promoter region contains
a unique Sad. These two sites were
then used for a double restriction di-
gestion to isolate the promoter region
and clone it in the EcoRI - Sad region
of the expression vector pMG36e. This
resulted in a replacement of the P32
promoter with the inducible nisin pro-
moter. Nisin promoter has been docu-
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mented to be a strong inducible pro-
moter (de Ruyter et al., 1996). The
replacement of the P32 promoter with
the nisin promoter theoretically will
improve on the expression ability of
the plasmid vector. The constructed
plasmid vector (pMG36eRnisA) re-
tained the ability of pMG36e to repli-
cate in E. coli as well as L lactis
MG1363. Thus, similarly to pMG36e,
the newly constructed vector has the
ability to use E. coli as an intermediate
host for molecular cloning purposes.
The amplification of the P32 promoter
together with the VP3 gene from the
previously constructed pMG36e-VP3
resulted in a peR product of about 700
bp. The digestion and cloning of the
PCR product into the KpnI - XbaI re-
gion of the plasmid pAl02 resulted in a
construction of a plasmid vector with
the potential to express the VP3 gene
of the CA V. The recombinant plasmid
also showed the ability to replicate in
both E. coli and L lactis thus allowing
the use of E. coli as an intermediate
host for molecular purposes.
Although these two plasmids have the
potential to be used in Lactococcus
expression system, they are currently
still in construction level. The effi-
ciency of protein expression in these
two newly constructed plasmids will be
studied in near future.
Conclusions
The VPl gene from chicken anemia
virus (CA V) was successfully cloned
into a commercially available expres-
sion vector pcDNA3.l and this recom-
binant DNA molecule showed the abil-
ity to express this VPl protein when
transfected into Vero cells. However,
the expression level was found to be
low. Subsequently, efforts have been
made to locally construct two expres-
sion vectors for Lactococcus expres-
sion system. The expression abilities of
these vectors are yet to be studied.
Benefits from the study
This study looks for an alternative
vaccine delivery system as well as
contributed in a deeper understanding
of using Lactococcus expression sys-
tem for vaccine delivery. Throughout
the course of this project, a total of 6
graduate and 14 undergraduate students
were trained in molecular techniques.
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